Litcius/Paper detail

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Javed Butler, Sanjiv J. Shah, Mark C. Petrie, Barry A. Borlaug, Steen Z. Abildstrøm, Melanie J. Davies, G. Kees Hovingh, Dalane W. Kitzman, Daniél Vega Møller, Subodh Verma, Mette Nygaard Einfeldt, Marie L.S. Lindegaard, Søren Rasmussen, Walter P. Abhayaratna, Fozia Ahmed, Tuvia Ben‐Gal, Vijay Chopra, Justin A. Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtěch Melenovský, Béla Merkely, Julio Núñez, Eduardo Perna, Morten Schou, Michele Senni, Kavita Sharma, Peter van der Meer, Dirk von Lewinski, Dennis Wolf, Mikhail Kosiborod

2024The Lancet323 citationsDOIOpen Access PDF

Topics & Concepts

Heart failure with preserved ejection fractionMedicineCardiologyInternal medicineSemaglutidePlaceboHeart failureEjection fractionType 2 diabetesDiabetes mellitusEndocrinologyAlternative medicinePathologyLiraglutideDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials | Litcius